Literature DB >> 25737988

Ibuprofen-mediated reversal of fluconazole resistance in clinical isolates of Candida.

Monika Sharma1, Debasis Biswas2, Aarti Kotwal3, Bhaskar Thakuria4, Barnali Kakati3, Bhupendra Singh Chauhan5, Abhishek Patras5.   

Abstract

INTRODUCTION: In view of the increasing prevalence of invasive Candidiasis in today's health-care scenario and the emergence of fluconazole resistance among clinical isolates of Candida, we sought to determine if Ibuprofen could elicit a reversal of fluconazole resistance and thereby offer a potential therapeutic breakthrough in fluconazole-resistant Candidiasis.
MATERIALS AND METHODS: We selected 69 clinical isolates of Candida, which demonstrated an MIC of >32 μg/ml for fluconazole, and subjected them to broth microdilution in presence and absence of Ibuprofen.
RESULTS: Forty two of the 69 isolates (60.9%) demonstrated reversal of Fluconazole resistance with concomitant use of Ibuprofen. This was characterized by significant species-wise variation (p=0.00008), with all the C. albicans isolates and none of the C. glabrata isolates demonstrating such reversal. Only 22.2% and 37.7% of C. krusei and C. tropicalis isolates respectively showed Ibuprofen-mediated reversal of Fluconazole resistance.
CONCLUSION: Since Ibuprofen is a known efflux pump inhibitor, our findings hint at the possible mechanism of Fluconazole resistance in most of our Candida isolates and suggest a potential therapeutic alternative that could be useful in the majority of Fluconazole-resistant clinical isolates of Candida.

Entities:  

Keywords:  Antifungal treatment; Candida; Efflux pump; Fluconazole resistance; Ibuprofen

Year:  2015        PMID: 25737988      PMCID: PMC4347079          DOI: 10.7860/JCDR/2015/10094.5494

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  26 in total

1.  Potent synergic effect between ibuprofen and azoles on Candida resulting from blockade of efflux pumps as determined by FUN-1 staining and flow cytometry.

Authors:  Cidália Pina-Vaz; Acácio Gonçalves Rodrigues; Sofia Costa-de-Oliveira; Elisabete Ricardo; Per-Anders Mårdh
Journal:  J Antimicrob Chemother       Date:  2005-08-22       Impact factor: 5.790

2.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

3.  Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil.

Authors:  Valério Rodrigues Aquino; Luciano W Lunardi; Luciano Zubaran Goldani; Afonso Luis Barth
Journal:  Braz J Infect Dis       Date:  2006-01-06       Impact factor: 1.949

4.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.

Authors:  R Arai; T Sugita; A Nishikawa
Journal:  Mycoses       Date:  2005-01       Impact factor: 4.377

Review 6.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.

Authors:  V Krcmery; A J Barnes
Journal:  J Hosp Infect       Date:  2002-04       Impact factor: 3.926

7.  Risk factors affecting in-hospital mortality in patients with nosocomial infections.

Authors:  Wang-Huei Sheng; Jann-Tay Wang; Mei-Shin Lin; Shan-Chwen Chang
Journal:  J Formos Med Assoc       Date:  2007-02       Impact factor: 3.282

8.  Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection.

Authors:  Donna M MacCallum; Alix Coste; Françoise Ischer; Mette D Jacobsen; Frank C Odds; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

9.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.

Authors:  Elisabete Ricardo; Sofia Costa-de-Oliveira; Ana Silva Dias; José Guerra; Acácio Gonçalves Rodrigues; Cidália Pina-Vaz
Journal:  FEMS Yeast Res       Date:  2009-03-30       Impact factor: 2.796

View more
  8 in total

1.  Synergistic Effect of Fluconazole and Calcium Channel Blockers against Resistant Candida albicans.

Authors:  Shuyuan Liu; Longtao Yue; Wenrui Gu; Xiuyun Li; Liuping Zhang; Shujuan Sun
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

2.  Effects of Aspirin as an Anti-inflammatory Drug on Azole-resistant Candida glabrata In Vitro.

Authors:  Sanaz Goodarzi; Seyyed Amin Ayatollahi Mousavi; Somayeh Sharifynia; Azar Berahmeh; Sassan Rezaie
Journal:  Iran J Public Health       Date:  2016-11       Impact factor: 1.429

3.  An Antifungal Mechanism of Protolichesterinic Acid from the Lichen Usnea albopunctata Lies in the Accumulation of Intracellular ROS and Mitochondria-Mediated Cell Death Due to Apoptosis in Candida tropicalis.

Authors:  S N Kumar; C Mohandas
Journal:  Front Pharmacol       Date:  2017-05-29       Impact factor: 5.810

4.  Screening of potential genes contributing to the macrocycle drug resistance of C. albicans via microarray analysis.

Authors:  Jing Yang; Wei Zhang; Jian Sun; Zhiqin Xi; Zusha Qiao; Jinyu Zhang; Yan Wang; Ying Ji; Wenli Feng
Journal:  Mol Med Rep       Date:  2017-09-20       Impact factor: 2.952

Review 5.  Pathogenesis and Clinical Relevance of Candida Biofilms in Vulvovaginal Candidiasis.

Authors:  Carmen Rodríguez-Cerdeira; Erick Martínez-Herrera; Miguel Carnero-Gregorio; Adriana López-Barcenas; Gabriella Fabbrocini; Monika Fida; May El-Samahy; José Luís González-Cespón
Journal:  Front Microbiol       Date:  2020-11-11       Impact factor: 5.640

6.  Fluconazole-COX Inhibitor Hybrids: A Dual-Acting Class of Antifungal Azoles.

Authors:  Rebecca Elias; Pallabita Basu; Micha Fridman
Journal:  J Med Chem       Date:  2022-01-27       Impact factor: 7.446

7.  In Vitro Anticandidal Activity and Mechanism of a Polyoxovanadate Functionalized by Zn-Fluconazole Complexes.

Authors:  Shuanli Guo; Wei Yang; Mingming Zhao; Rui Tian; Boyu Zhang; Yanfei Qi
Journal:  Molecules       Date:  2018-05-09       Impact factor: 4.411

8.  Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study.

Authors:  Shereen A Sayed; Ehsan A B Hassan; Muhamad R Abdel Hameed; Michael N Agban; Mostafa F Mohammed Saleh; Hayam H Mohammed; Abu-Baker M Abdel-Aal; Sherein G Elgendy
Journal:  J Blood Med       Date:  2021-06-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.